SEARCH

SEARCH BY CITATION

References

  • 1
    Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003; 101: 376577.
  • 2
    Van Der Poll T, De Jonge E, Levi M. Regulatory role of cytokines in disseminated intravascular coagulation. Semin Thromb Hemost 2001; 27: 63951.
  • 3
    Levi M, Ten Cate H, Van Der Poll T. Endothelium: interface between coagulation and inflammation. Crit Care Med 2002; 30: S2204.
  • 4
    Taylor FB Jr, Chang A, Ruf W, Morrissey JH, Hinshaw L, Catlett R, Blick K, Edgington TS. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991; 33: 12734.
  • 5
    Carr C, Bild GS, Chang AC, Peer GT, Palmier MO, Frazier RB, Gustafson ME, Wun TC, Creasey AA, Hinshaw LB, Taylor FB, Galluppi GR. Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock. Circ Shock 1994; 44: 12637.
  • 6
    Creasey AA, Chang AC, Feigen L, Wun TC, Taylor FB Jr, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993; 91: 28506.
  • 7
    Taylor FB, Chang AC, Peer G, Li A, Ezban M, Hedner U. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli. Blood 1998; 91: 160915.
  • 8
    Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr. Efficacy and safety of recombinant human activated protein C for treatment of patients with severe sepsis. N Engl J Med 2001; 344: 699709.
  • 9
    Dhainaut JF, Yan SB, Joyce DE, Pettila V, Basson B, Brandt JT, Sundin DP, Levi M. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004; 2: 192433.
  • 10
    Reitsma PH, Branger J, Van Den Blink B, Weijer S, Van Der Poll T, Meijers JC. Procoagulant protein levels are differentially increased during human endotoxemia. J Thromb Haemost 2003; 1: 101923.
  • 11
    Bone RC. Modulators of coagulation. A critical appraisal of their role in sepsis. Arch Intern Med 1992; 152: 13829.
  • 12
    Hesselvik JF, Blombäck M, Brodin B, Maller R. Coagulation, fibrinolysis and kallikrein system in sepsis: relation to outcome. Crit Care Med 1989; 17: 72433.
  • 13
    Kreuter M, Retzlaff S, Enser-Weis U, Berdel WE, Mesters RM. Acquired haemophilia in a patient with gram-negative urosepsis and bladder cancer. Haemophilia 2005; 11: 1815.
  • 14
    Laporte F, Cestac P, Favre V, DeRoch XS, Khatibi S, Bonnet E, Massip P, Sie P, Bellon B. Treatment of a septic patient with acquired haemophilia. Rev Med Interne 2003; 24: 6925.
  • 15
    Yee TT, Cohen BJ, Pasi KJ, Lee CA. Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate. Br J Haematol 1996; 93: 4579.
  • 16
    Iversen N, Strekerud FG, Abildgaard U. Tissue factor pathway inhibitor (TFPI) in disseminated intravascular coagulation: low levels of the activated factor X-TFPI complex. Blood Coagul Fibrinolysis 2000; 11: 5918.
  • 17
    Gando S, Kameue T, Matsuda N, Hayakawa M, Morimoto Y, Ishitani T, Kemmotsu O. Imbalances between the levels of tissue factor and tissue factor pathway inhibitor in ARDS patients. Thromb Res 2003; 109: 11924.
  • 18
    Gando S, Nanzaki S, Morimoto Y, Ishitani T, Kemmotsu O. Tissue factor pathway inhibitor response does not correlate with tissue factor-induced disseminated intravascular coagulation and multiple organ dysfunction syndrome in trauma patients. Crit Care Med 2001; 29: 2626.
  • 19
    Gando S, Kameue T, Morimoto Y, Matsuda N, Hayakawa M, Kemmotsu O. Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit Care Med 2002; 30: 172934.
  • 20
    Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995; 10: 11921.
  • 21
    Bi L, Sarkar R, Naas T, Lawler AM, Pain J, Shumaker SL, Bedian V, Kazazian HH Jr. Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies. Blood 1996; 88: 344650.
  • 22
    Sewnath ME, Olszyna DP, Birjmohun R, Ten Kate FJ, Gouma DJ, Van Der Poll T. IL-10-deficient mice demonstrate multiple organ failure and increased mortality during Escherichia coli peritonitis despite an accelerated bacterial clearance. J Immunol 2001; 166: 632331.
  • 23
    Weijer S, Schoenmakers SH, Florquin S, Levi M, Vlasuk GP, Rote WE, Reitsma PH, Spek CA, Van Der Poll T. Inhibition of the tissue factor-factor VIIa pathway does not influence the inflammatory or antibacterial response to Escherichia coli peritonitis in mice. J Infect Dis 2004; 189: 230817.
  • 24
    Muchitsch EM, Turecek PL, Zimmermann K, Pichler L, Auer W, Richter G, Gritsch H, Schwarz HP. Phenotypic expression of murine hemophilia. Thromb Haemost 1999; 82: 13713.
  • 25
    Levi M, Ten Cate H, Bauer KA, Van Der Poll T, Edgington TS, Buller HR, Van Deventer SJ, Hack CE, Ten Cate JW, Rosenberg RD. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994; 93: 11420.
  • 26
    De Jonge E, Dekkers PE, Creasey AA, Hack CE, Paulson SK, Karim A, Kesecioglu J, Levi M, Van Deventer SJ, Van Der Poll T. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000; 95: 11249.
  • 27
    Schoenmakers SH, Reitsma PH, Spek CA. Blood coagulation factors as inflammatory mediators. Blood Cells Mol Dis 2005; 34: 307.
  • 28
    Gilbert MS, Aledort LM, Seremetis S, Needleman B, Oloumi G, Forster A. Long term evaluation of septic arthritis in hemophilic patients. Clin Orthop Relat Res 1996; 328: 549.
  • 29
    Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet 2003; 361: 18019.